Vyome Holdings (HIND) Other Non-Current Liabilities (2015 - 2026)
Vyome Holdings (HIND) posted quarterly Other Non-Current Liabilities of $323066.0 for Q1 2026, down 71.05% year-over-year from $1.1 million in Q1 2025, and little changed quarter-over-quarter from $323066.0 in Q4 2025.
Vyome Holdings (HIND) Other Non-Current Liabilities (2015 - 2026) Analysis & Trends
Vyome Holdings' Other Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $323066.0 for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 71.05% year-over-year to $323066.0; the TTM figure through Mar 2026 stood at $323066.0 (down 71.05% YoY), while the FY2025 annual figure was $323066.0, up 406.41% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $323066.0, roughly flat from $323066.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $1.1 million in Q1 2025, with the low at $5000.0 in Q2 2022.
- The 5-year median for Other Non-Current Liabilities is $86000.0 (2023), against an average of $275637.6.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities surged 10140.0% in 2023, then tumbled 94.86% in 2024.
- Vyome Holdings' Other Non-Current Liabilities stood at $5000.0 in 2022, then surged by 1340.0% to $72000.0 in 2023, then slipped by 11.4% to $63795.0 in 2024, then surged by 406.41% to $323066.0 in 2025, then changed by 0.0% to $323066.0 in 2026.
- Business Quant data shows HIND's Other Non-Current Liabilities at $323066.0 in Q1 2026, $323066.0 in Q4 2025, and $180000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Vyome Holdings | 16.07 Mn | 8.18 Mn | 11,658.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 269,241.00 |
| Mar 31, 2026 | 323,066.00 |
| Dec 31, 2025 | 323,066.00 |
| Sep 30, 2025 | 180,000.00 |
| Mar 31, 2025 | 1.12 Mn |
| Dec 31, 2024 | 63,795.00 |
| Sep 30, 2024 | 26,000.00 |
| Jun 30, 2024 | 54,000.00 |
| Mar 31, 2024 | 51,000.00 |
| Dec 31, 2023 | 72,000.00 |
| Sep 30, 2023 | 100,000.00 |
| Jun 30, 2023 | 512,000.00 |
| Mar 31, 2023 | 992,000.00 |
| Jun 30, 2022 | 5,000.00 |
| Mar 31, 2022 | 41,000.00 |
| Dec 31, 2021 | 300,000.00 |
| Sep 30, 2021 | 1.30 Mn |
| Jun 30, 2021 | 38,000.00 |
| Mar 31, 2021 | 38,000.00 |
| Dec 31, 2020 | 1.02 Mn |